The Vitae Pharmaceuticals business model is to address the critical issues confronting the industry’s small molecule drug research efforts: Innovation, Speed and Capital Efficiency.
We address high unmet medical need conditions using a novel structure-based drug discovery engine run by world-class discovery and early development scientists targeting known, promising, hard-to-drug targets. Vitae Pharmaceuticals’ three lead programs demonstrate our ability to achieve innovation, speed and capital efficiency in drug discovery.
Vitae Pharmaceuticals Performance Record:
Meeting Goals of Innovation, Speed and Capital Efficiency
|Time to achieve|
|Novel, patentable structures||Animal PD
|Value realization via deal||Upfront committed cash||Year|
|Renin||7 mos.||14 mos.||wholly owned by Vitae||n/a||n/a|
|11ß-HSD-1||2 mos.||16 mos.||21 mos.||$37 MM||2007|
|BACE||6 mos.||14 mos.||18 mos.||$42 MM||2009|
Innovation / Speed
On average, Vitae Pharmaceuticals' discovery engine has produced novel leads with animal proof-of-concept data within 14-16 months. This includes assay development, generation of crystal structures, SBDD using proprietary platform, etc.
The annual incremental cost of a Vitae Pharmaceuticals discovery program is ~$5 million; and time from program start-to-deal has consistently been under 2 years.